Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GMAB stock hub

Genmab A/S has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GMABis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

15.9B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GMAB

In the news

Latest news · GMAB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E19.2

P25 12.3P50 18.4P75 33.1

Trailing P/E19.3

P25 14.9P50 23.2P75 38.5

ROE15

P25 -105.6P50 -46.5P75 -3.1

ROIC10.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GMAB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

256

Groups with data

Currency

USD

Showing 256 of 256 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001434265
Company name	Genmab A/S
Country	Denmark
Country code	US
Cusip	372303206
Employees	2,973
Employees Change	339%
Employees Change Percent	12.87
Enterprise value	$19.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US3723032062
Last refreshed	2026-05-10
Market cap	$15.9B
Market cap category	Large-Cap
Price	$26.43
Price currency	USD
Rev Per Employee	1,312,142.62x
Sector	Healthcare
Sic	2834
Symbol	GMAB
Website	https://www.genmab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.17%
EV Earnings	24.1x
EV Sales Forward	4.4x
EV/EBIT	15.37x
EV/EBITDA	14.87x
EV/FCF	22.69x
EV/Sales	5.07x
FCF yield	5.49%
Forward P/E	19.16x
P/B ratio	2.79x
P/E ratio	19.34x
P/S ratio	4.07x
PE Ratio10 Y	43.38x
PE Ratio3 Y	21.58x
PE Ratio5 Y	32.49x
PS Forward	3.53x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	32.99%
EBITDA Margin	34.09%
FCF margin	22.35%
Gross margin	93.31%
Gross Profit	$3.6B
Gross Profit Growth	18.37%
Gross Profit Growth Q	23.48%
Gross Profit Growth3 Y	17.93%
Gross Profit Growth5 Y	16.39%
Net Income	$821M
Net Income Growth	-27.73%
Net Income Growth Q	-72.82%
Net Income Growth Years	0%
Net Income Growth3 Y	2.7%
Net Income Growth5 Y	-1.41%
Pretax Margin	26.51%
Profit Margin	21.05%
Profit Per Employee	$276,152
Profitable Years	9
ROA	8.48
Roa5y	10.27
ROCE	11.49
ROE	14.96
Roe5y	18.28
ROIC	10.72
Roic5y	66.47

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.08%
Cagr1y	28.32%
Cagr3y	-13.17%
Cagr5y	-6.71%
EPS Growth	-25.81
EPS Growth Q	-72.79
EPS Growth Years	0
EPS Growth3 Y	4.5
EPS Growth5 Y	-0.38
FCF Growth	-24.76%
FCF Growth3 Y	-1.18%
FCF Growth5 Y	0.36%
OCF Growth	-24.46%
OCF Growth Q	-98.96%
OCF Growth10 Y	32.34%
OCF Growth3 Y	-1.94%
OCF Growth5 Y	0.04%
Revenue Growth	20.66x
Revenue Growth Q	25.32x
Revenue Growth Quarters	19x
Revenue Growth Years	4x
Revenue Growth3 Y	20.68x
Revenue Growth5 Y	18.01x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.41
Assets	$12.4B
Cash	$1.5B
Current Assets	$2.6B
Current Liabilities	$1.2B
Debt	$5.4B
Debt EBITDA	$3.97
Debt Equity	$0.94
Debt FCF	$6.14
Equity	$5.7B
Interest Coverage	7.66
Liabilities	$6.7B
Long Term Assets	$9.8B
Long Term Liabilities	$5.5B
Net Cash	$-3.8B
Net Cash By Market Cap	$-24.1
Net Debt EBITDA	$2.88
Net Debt Equity	$0.67
Net Debt FCF	$4.39
Tangible Book Value	$-3.6B
Tangible Book Value Per Share	$-58.99
WACC	6.67

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.18
Inventory Turnover	15.82
Net Working Capital	$163M
Quick ratio	2.17
Working Capital	$1.4B
Working Capital Turnover	$1.67

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.55%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	80.41%
1Y total return	28.3%
200-day SMA	28.92
3Y total return	-34.53%
50-day SMA	27.2
50-day SMA vs 200-day SMA	50under200
5Y total return	-29.33%
All Time High	49.07
All Time High Change	-46.14%
All Time High Date	2021-09-02
All Time Low	2.8
All Time Low Change	843.25%
All Time Low Date	2013-06-24
ATR	0.84
Beta	0.7
Ch YTD	-14.19
High	26.76
High52	35.43
High52 Date	2026-01-14
High52ch	-25.4%
Low	25.34
Low52	18.89
Low52 Date	2025-05-13
Low52ch	39.95%
Ma50ch	-2.82%
Premarket Change Percent	-5.36
Premarket Price	$25.61
Premarket Volume	259,170
Price vs 200-day SMA	-8.59%
RSI	43.07
RSI Monthly	47.96
RSI Weekly	43.38
Sharpe ratio	0.79x
Sortino ratio	1.3
Total Return	2.55%
Tr YTD	-14.19
Tr1m	-4.41%
Tr1w	-0.08%
Tr3m	-14.47%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	3
Analyst Price Target Top	$38
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.17
Earnings EPS Estimate Growth	-45.16
Earnings Revenue Estimate	4,711,724,816x
Earnings Revenue Estimate Growth	558.98x
Operating Income	$1.3B
Operating Income Growth	18.4
Operating Income Growth Q	19.68
Operating Income Growth3 Y	12.44
Operating Income Growth5 Y	3.72
Operating margin	32.99
Price target	$39.56
Price Target Change	$49.68
Price Target Change Top	$43.78

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60,664,302%
Float Percent	98.83%
Net Borrowing	5,420,000,000
Shares Insiders	1.18%
Shares Institutions	60.68%
Shares Out	61,383,670
Shares Qo Q	1.17%
Shares Yo Y	-2.55%
Short Ratio	5.05
Short Shares	1.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$720M
Average Volume	1,866,396.65x
Bv Per Share	92.57
CAPEX	$-30M
Ch10y	80.41
Ch1m	-4.41
Ch1w	-0.08
Ch1y	28.3
Ch3m	-14.47
Ch3y	-34.53
Ch5y	-29.33
Ch6m	-7.78
Change	-2.33%
Change From Open	3.4
Close	27.06
Days Gap	-5.54
Depreciation Amortization	43,000,000
Dollar Volume	156,449,239.8
Earnings Date	2026-05-07
EBIT	$1.3B
EBITDA	$1.3B
EPS	$13.11
F Score	4
FCF	$872M
FCF EV Yield	4.41x
FCF Per Share	$14.21
Financing CF	4,625,000,000
Fiscal Year End	December
Founded	1,999
Goodwill	355,000,000
Graham Number	17.05628
Graham Upside	-35.47
Income Tax	$213M
Investing CF	-5,609,000,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2018-05-01
Last Split Type	Forward
Last10k Filing Date	2026-02-17
Lynch Fair Value	$6.83
Lynch Upside	-74.14
Ma150	30.02
Ma150ch	-11.95%
Ma20	27.42
Ma20ch	-3.61%
Net CF	-98,000,000
Next Earnings Date	2026-08-06
Open	25.56
Optionable	Yes
P FCF Ratio	18.21
P OCF Ratio	17.6
Position In Range	76.76
Post Close	26.43
Postmarket Change Percent	1.83
Postmarket Price	$26.91
Ppne	265,000,000
Pre Close	27.06
Price Date	2026-05-08
Price EBITDA	$11.94
Relative Volume	3.17x
Revenue	3,901,000,000x
SBC By Revenue	3.9x
Share Based Comp	152,000,000
Tax By Revenue	5.46x
Tax Rate	20.6%
Tr6m	-7.78%
Volume	5,919,381
Z Score	2.72

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GMAB pay a dividend?

Capital-return profile for this ticker.

Performance

GMAB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GMAB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+60.7%

Float: +98.8% of shares outstanding

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GMAB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.1

Neutral momentum band

Price vs 200-day MA

-8.6%

50/200-day relationship not available

Beta (5Y)

0.69

Less volatile than the market

Sharpe ratio

0.79

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GMAB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GMAB stock rating?

Genmab A/S is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GMAB analysis?

The full report lives at /stocks/GMAB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GMAB?

The latest report frames GMAB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GMAB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.